PO.TB10.04 · 肿瘤生物学
转移性癌症免疫治疗过程中肿瘤内TCR库的纵向与空间异质性
Longitudinal and spatial heterogeneity of intra-tumoral TCR repertoires during immunotherapy in metastatic cancers
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:T细胞受体(TCR)图谱的空间与时间异质性及演变可能影响免疫治疗结局。研究TCR库及其抗原特异性,并结合T细胞动态,可为深入了解抗肿瘤免疫应答的质量及其对癌症免疫治疗有效性的影响提供重要见解。
方法:我们在7例转移性肺癌及头颈癌患者接受含免疫治疗方案的临床病程中,于关键时间点进行了系列及多区域取样(n=52份样本)。为研究TCR库,我们对TCR-beta CDR3区域进行了bulk TCR测序,回收了69,135个独特的功能性克隆(ImmunoSeq检测,Adaptive Biotechnologies)。为确定不同肿瘤部位及患者对免疫治疗的差异性应答,我们基于克隆型频率与身份,采用Morisita重叠指数(MI)评估TCR库相似性。随后,我们使用GIANA对抗原特异性相似的TCR克隆进行聚类(15,476个簇),并在克隆及簇层面进行差异性T细胞丰度分析以评估T细胞动态。采用Fisher精确检验确定具有统计学意义的TCR扩增与消退(p≤0.05)。我们使用VDJDB与CEDAR数据库对2,019个TCR簇进行去孤儿化,将其映射至已知抗原特异性的TCR。
结果:我们发现患者之间存在显著的TCR库异质性(患者间MI≈0),提示患者层面的私有TCR图谱。在个体患者中,原发部位与转移部位之间存在较高异质性(基线-转移MI=0.01-0.34),而来自邻近解剖位置的转移部位其TCR库则具有相似性(邻近转移MI=0.47-0.96)。尽管每例患者中扩增的簇与克隆大多为私有,但在免疫治疗背景下,消退肿瘤与进展肿瘤中观察到相似的动态;而在尸检部位,显著扩增的簇主导了各自的TCR库(丰度14-28%)。识别病毒抗原表位的TCR序列,如GLCTLVAML(EBV)、KLGGALQAK(CMV)和RAKFKQLL(EBV),在多例患者中被识别出,并且是进展性转移部位中显著扩增簇的组成部分。检测到若干显著扩增的TCR簇(FDR p≤0.05);尽管这些簇的抗原特异性未被映射,但它们可能识别与激发抗肿瘤免疫应答相关的肿瘤抗原及突变相关新抗原。
结论:空间与时间层面的TCR库分析有助于更好地理解患者在治疗期间的免疫图谱,并提供了可用于进一步剖析免疫治疗背景下适应性免疫应答异质性的见解。
查看英文原文 English abstract
Introduction: Spatial and temporal heterogeneity and evolution of the T cell receptor (TCR) landscape may influence immunotherapy outcomes. Studying TCR repertoires and their antigen specificities, together with T cell dynamics, could provide important insights into the quality of anti-tumor immune responses and their impact on cancer immunotherapy effectiveness.
Methods: We performed serial and multi-region sampling at critical timepoints (n=52 samples) during the clinical course of 7 patients with metastatic lung and head and neck cancer, who received immunotherapy-containing regimens. To study the TCR repertoire, we performed bulk TCR sequencing of TCR-beta CDR3 regions and recovered 69,135 unique productive clones (ImmunoSeq assay, Adaptive Biotechnologies). To determine differential responses to immunotherapy across tumor sites and patients, we evaluated TCR repertoire similarity using Morisita's overlap index (MI) based on clonotype frequency and identity. Next, we clustered TCR clones of similar antigen specificities using GIANA (15,476 clusters) and performed differential T cell abundance analyses at the clone- and cluster-level to assess T cell dynamics. Statistically significant TCR expansions and regressions were determined using Fisher's exact test (p≤0.05). We used the VDJDB and CEDAR databases to de-orphanize 2,019 TCR clusters, mapping to TCRs with known antigen specificities.
Results: We found significant TCR repertoire heterogeneity between patients (MI between patients ≈ 0), suggesting private TCR landscapes at a patient level. In individual patients, a higher heterogeneity was noted between primary and metastatic sites (MI baseline-metastatic = 0.01 - 0.34) while TCR repertoires of metastatic sites from proximal anatomic locations shared similarities (MI proximal metastasis = 0.47 - 0.96). Despite the largely private expanded clusters and clones in each patient, similar dynamics were observed in regressing compared to progressing tumors in the context of immunotherapy, while at the autopsy sites, significantly expanded clusters dominated their respective TCR repertoires (14-28% abundance). TCR sequences recognizing viral antigen epitopes, such as GLCTLVAML (EBV), KLGGALQAK (CMV) and RAKFKQLL (EBV) were identified across patients and were part of the significantly expanded clusters in progressing metastatic sites. Several significantly expanding TCR clusters (FDR p≤0.05) were detected; while these had unmapped antigen specificity, they could recognize tumor antigens and mutation-associated neoantigens relevant for mounting anti-tumor immune responses.
Conclusions: Spatial and temporal TCR repertoire analyses provided a better understanding of the patients' immune landscape during therapy and offered insights that can be used to further dissect the heterogeneity of adaptive immune responses in the context of immunotherapy.
利益披露 Disclosure
A. Zoitou, None..
S. Velculescu, None..
G. Pereira, None..
A. Balan, None..
M. Najjar, None..
A. Jamali, None.
J. R. White,
Resphera Biosciences Other Business Ownership, Founder.
R. Karchin, None..
N. Niknafs, None.
H. Kang,
Eli-Lilly ).
Remix Therapeutics ).
Merus ).
NeoImmuneTech ).
PDS Biotechnology ).
PIN therapeutics Other, Consultant.
Coherus Other, Consultant.
MitoImmune Other, Data safety monitoring board member.
HLB Group Advisory board member.
P. M. Forde,
AstraZeneca ), Other, Consultant/advisory role.
Bristol Myers Squibb ), Other, Consultant/advisory role.
Novartis ), Other, Consultant/advisory role.
Regeneron ), Other, Consultant/advisory role.
Kyowa ).
BioNTech ), Other, Consultant/advisory role.
AbbVie Other, Consultant/advisory role.
Amgen Other, Consultant/advisory role.
Ascendis Other, Consultant/advisory role.
ChromaCode Other, Consultant/advisory role.
Daiichi Sankyo Other, Consultant/advisory role.
F-Star Other, Consultant/advisory role.
Genelux Other, Consultant/advisory role.
Gilead Other, Consultant/advisory role.
iTeos Other, Consultant/advisory role.
Novocure Other, Consultant/advisory role.
Tavotek Other, Consultant/advisory role.
Teva Consultant/advisory role.
Genentech Other, Consultant/advisory role.
Sanofi, Surface, Janssen, G1, Merck, Polaris, Flame Other, Consultant/advisory role, DSMB member.
C. L. Hann,
AbbVie ), Other, Consultant.
Amgen ), Other, Consultant.
AstraZeneca ), Other, Consultant, scientific advisory board.
Daiichi Sankyo ), Other, Scientific advisory board.
J. E. Hooper, None.
J. R. Brahmer,
AstraZeneca ), Other, Consultant/advisory role.
Bristol Myers Squibb ).
RAPT Therapeutics Other, Consultant/advisory role.
Mestag Other, Consultant/advisory role.
GlaxoSmithKline Other, Consultant/advisory role.
Amgen Other, Consultant/advisory role.
Sanofi Aventis Other, Consultant/advisory role.
Summit Therapeutics Other, Consultant/advisory role.
Genentech Other, Consultant/advisory role.
Beyer Other, Consultant/advisory role.
Genmab Other, Data Safety and Monitoring Board.
V. Anagnostou,
Astra Zeneca ), Other, Advisory board member.
Bristol-Myers Squibb ).
Personal Genome Diagnostics/Labcorp ).
Delfi Diagnostics ).
Neogenomics Advisory board member.
Foundation Medicine Other, Honoraria.
Personal Genome Diagnostics Other, Honoraria.
Roche Other, Honoraria.
ThermoFisher Other, Honoraria.
Guardant Health Other, Honoraria.